




Apico 2021

Apicolipid Team

Lipid metabolism, Host-pathogen metabolic interactions, & metabolism in health




Apico 2022



Jean Roget site
health campus



Apico 2025



Dedicated facilities



Apico 2024



Apico 2023




Apicolipid and Gemeli lipidomics: a shared development for mutual benefits

More than 20000 samples analyzed, 35+ projects, 20+ papers

IBISA • Infrastructures
en Biologie
Santé et
Agriculture

La Région
Auvergne-Rhône-Alpes

Programme IRiCE, 1.5 M€



Yoshiki Yamaryo-Botté, IR IAB-UGA, "the Brain" behind lipid analysis

All targeted and untargeted analyses on any aqueous and polar metabolite via NMR and MS approaches, analyses of metabolic fluxes using stable isotope labeling, lipid signaling, host pathogen metabolic interactions, cohorts, metabolic signatures...

Equipements MÉTABOLOMIQUE-LIPIDOMIQUE

GC-MS

Agilent 5970

Analyses métabolomique, lipidomique et fluxomique non-ciblées

LC-MS QqQ

Agilent 6495c

Analyses métabolomique, lipidomique et fluxomique ciblées haut débit

Acquisitions en cours
Crédit-bail 2021-2024

Equipements existants

2015

2017

2018

2019

2020

2021

Apicolipid
Lipidomique/
fluxomique



TIMC
HPLC/MS

GeXim




B. Elena-Hermann
¹H-RMN

2018: accréditation P3*
MESRI- Haut Comité
des biotechnologies




La Région
Auvergne-Rhône-Alpes

Programme IRiCE: Gemeli
1.5 M€





Applications for drug target/development- ex: Lysophospholipase as drug target



Dass and Shunmugam et al. Nature Communications 2021



Merci!

←
Apicolipid IAB